IV Choline Chloride
Intestinal Failure-Associated Liver Disease (IFALD)
Key Facts
Indication
Intestinal Failure-Associated Liver Disease (IFALD)
Phase
Phase 2
Status
Active, completed enrollment
Company
About Protara Therapeutics
Protara Therapeutics is a clinical-stage biotech company with a mission to develop transformative therapies for cancer and rare diseases. Its strategy centers on advancing two distinct, late-stage clinical programs: TARA-002, an investigational cell therapy for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, a phospholipid substrate replacement for intestinal failure-associated liver disease. The company has achieved key milestones by initiating and enrolling multiple Phase 2 trials, positioning both assets for potential near-term data readouts. Protara's focused approach aims to address high-need, niche markets with limited treatment options.
View full company profileTherapeutic Areas
Other Intestinal Failure-Associated Liver Disease (IFALD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Orziloben | NorthSea Therapeutics | Phase 2 |